Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial

JAMA

Volumn 288, Issue 19, 2002, Pages 2421-2431

  Wright, Jackson T ^a   Bakris, George ^a   Greene, Tom ^a   Agodoa, Larry Y ^a   Appel, Lawrence J ^a   Charleston, Jeanne ^a   Cheek, DeAnna ^a   Douglas Baltimore, Janice G ^a   Gassman, Jennifer ^a   Glassock, Richard ^a   Hebert, Lee ^a   Jamerson, Kenneth ^a   Lewis, Julia ^a   Phillips, Robert A ^a   Toto, Robert D ^a   Middleton, John P ^a   Rostand, Stephen G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDRALAZINE; METOPROLOL; MINOXIDIL; RAMIPRIL;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NEGRO; NEPHROSCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 0037145856     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.19.2421     Document Type: Article

References (52)

1. US Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999. Available at: http://www.usrds.org/chapters/begin.pdf. Accessibility verified October 3, 2002.
2. Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am. 1997;26:125-144.
3. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
4. Whelton PK, Perneger TV, He J, Klag MJ. The role of blood pressure as a risk factor for renal disease. J Hum Hypertens. 1996;10:683-689.
5. National High Blood Pressure Education Program Working Group. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med. 1996;156:1938-1947.
6. Woods JW, Blythe WB, Huffines WD. Management of malignant hypertension complicated by renal insufficiency. N Engl J Med. 1974;291:10-14.
7. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
8. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995;123:754-762.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
10. Klag MJ, Whelton PK, Randall BL, et al. Endstage renal disease in African-American and white men: 16-Year MR-FIT findings. JAMA. 1997;277:1293-1298.
11. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995;123:754-762.
12. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension. 1989;13:180-193.
13. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684-688.
14. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA. 1992;268:3085-3091.
15. Striker GE. Kidney disease and hypertension in blacks. Am J Kidney Dis. 1992;20:673.
16. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality. Arch Intern Med. 2001;161:1183-1192.
17. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: Findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-2018.
18. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
19. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis. 2000;36:646-661.
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
21. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension. 1997;30:428-435.
22. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-750.
23. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patientlevel data. Ann Intern Med. 2001;135:73-87.
24. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
25. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
26. Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17(suppl 4):3S-16S.
27. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643.
28. Lewis J, Agodoa L, Cheek D, et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis. 2001;38:744-753.
29. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis. 1997;29:720-728.
30. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
31. De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino MV. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol. 1993;22:208-214.
32. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
33. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med. 2000;160:685-693.
34. Modification of Diet in Renal Disease Study Group. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-2109.
35. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359-364.
36. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963-974.
37. Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data, Oxford, England: Clarendon Press; 1994.
38. Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial. Kidney Int. 1997;51:244-252.
39. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):854-864.
40. Toto RD, Mitchell HC, Smith RD, et al. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995; 48:851-859.
41. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
42. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
43. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
44. Smith GD, Phillips AN. Confounding in epidemiological studies: Why "independent" effects may not be all they seem. BMJ. 1992;305:757-759.
45. Pocock SJ. The justification for randomized clinical trials. In: Clinical Trials: A Practical Approach. New York, NY: Wiley; 1983:50-65.
46. Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991 [published correction appears in Hypertension. 1996;27: 1192]. Hypertension. 1995;26:60-69.
47. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
48. Guasch A, Parham M, Zayas CF, et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol. 1997;8:793-798.
49. Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol. 1998;9:2096-2101.
50. Locatelli F, Carbarns IR, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. Kidney Int Suppl. 1997;63:S63-S66.
51. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
52. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178-187.